Dexamethasone Treatment for Sepsis-associated Acute Respiratory Distress Syndrome: a Multicenter, Randomised, Double-blinded, Controlled Trial (DEFEND)
Acute respiratory distress syndrome (ARDS) is a major cause of acute hypoxemic respiratory failure in critically ill patients and is associated with substantial mortality. Current management is largely supportive, and no pharmacologic therapy has been shown consistently to reduce mortality in a broad population of patients with ARDS. Inflammation plays a central role in the pathogenesis of ARDS. Excessive inflammatory activation contributes to alveolar-capillary injury, impaired gas exchange, and progression of organ dysfunction. Glucocorticoids may mitigate these processes and have been associated in some studies with improved clinical outcomes, including shorter duration of mechanical ventilation. However, the effect of glucocorticoids on survival remains uncertain.
ARDS is a heterogeneous syndrome with diverse etiologies, and treatment response may vary according to the underlying cause. A post hoc analysis of the Dex-ARDS trial suggested that the treatment effect of glucocorticoids may be greater in ARDS caused by pneumonia or extrapulmonary sepsis. In a cross-sectional survey of 135 patients with ARDS from 20 ICUs in China, pneumonia- and extrapulmonary sepsis-associated ARDS accounted for 77.6% of cases, indicating that these are the predominant etiologic subtypes encountered in clinical practice in China. More importantly, compared with ARDS attributable to other causes, pneumonia- and extrapulmonary sepsis-associated ARDS has been associated with higher mortality, suggesting a greater disease burden, worse prognosis, and a more urgent need for improved treatment strategies. On this basis, the present trial will enroll patients with ARDS caused by sepsis, including pneumonia and extrapulmonary sepsis.
The primary hypothesis of this study is that, among patients with sepsis-associated ARDS, dexamethasone plus usual care, as compared with placebo plus usual care, will reduce 90-day all-cause mortality. We therefore designed a multicenter, randomized, double-blind, controlled trial to evaluate the clinical efficacy of dexamethasone in patients with sepsis-associated ARDS. The primary objective is to compare dexamethasone plus usual care with placebo plus usual care with respect to 90-day all-cause mortality.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: hui chen, MD
- Telefonnummer: +86-18006138640
- E-mail: huichen.icu@gmail.com
Studiesteder
-
-
-
Nanjing, Kina
- Rekruttering
- Zhongda Hospital, School of Medicine, Southeast University
-
Kontakt:
- hui chen, MD
- Telefonnummer: +86-18006138640
- E-mail: huichen.icu@gmail.com
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210009
- Ikke rekrutterer endnu
- Zhongda Hospital, School of Medicine, Southeast University
-
Kontakt:
- Jianfeng Xie, MD
- Telefonnummer: +86-13770332331
- E-mail: xie820405@126.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Suspected or confirmed infection
- Receipt of invasive mechanical ventilation with a positive end-expiratory pressure (PEEP) of at least 5 cm H₂O, noninvasive positive-pressure ventilation with a PEEP of at least 5 cm H₂O, or high-flow nasal oxygen therapy with a flow rate of at least 30 L/min
- Acute-onset ARDS, defined as ARDS diagnosed for at least 6 hours but no more than 72 hours, according to the following criteria:
(1) New or worsening respiratory symptoms or respiratory failure (2) Pulmonary infiltrates on chest radiography or computed tomography, or B-lines or consolidation on lung ultrasonography, not fully explained by pleural effusion, lobar or whole-lung collapse or atelectasis, or pulmonary nodules. Patients with unilateral pulmonary infiltrates, B-lines, or consolidation are eligible (3) Respiratory failure not fully explained by cardiac failure or fluid overload (4) Hypoxemia defined as PaO₂/FiO₂ of 300 mm Hg or less, or SpO₂/FiO₂ of 315 or less, with SpO₂ no greater than 97%.
Exclusion Criteria:
- Pregnancy
- Planned withdrawal of life-sustaining treatment within the next 24 hours
- Current hospitalization for more than 7 days before screening;
- Clinical improvement within the 48 hours before randomization, based on the investigator's overall assessment
- Highly suspected or confirmed COVID-19 infection
- Severe chronic obstructive pulmonary disease, defined as a PaCO₂ ≥ 60 mmHg in a stable condition, or the need for long-term oxygen therapy, excluding CPAP/BiPAP prescribed exclusively for sleep-disordered breathing.
- Congestive heart failure (NYHA III-IV)
- A definite clinical indication for high-dose corticosteroids at screening, defined as a maximum daily dose exceeding hydrocortisone 200 mg or an equivalent glucocorticoid dose
- Contraindications to short-term dexamethasone, including untreated systemic fungal infection, active tuberculosis, active viral hepatitis, or major upper gastrointestinal bleeding
- Known hypersensitivity to dexamethasone
- Participation in another interventional clinical trial within the previous 30 days
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Dexamethasone Group
Dexamethasone plus usual care
|
Participants assigned to dexamethasone will receive 20 mg intravenously as soon as possible after randomization.
Beginning after 10:00 am on the next calendar day following randomization, dexamethasone 20 mg will be administered once daily through day 5, followed by dexamethasone 10 mg once daily from Day 6 to Day 10.
Andre navne:
|
|
Placebo komparator: Placebo Group
Placebo plus usual care
|
Participants assigned to the placebo group will receive 0.9% sodium chloride injection as matching placebo, administered according to the same schedule as dexamethasone
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
90-day all-cause mortality
Tidsramme: From randomization (day 0) to day 90 (inclusive)
|
The proportion of participants who die from any cause between randomization (day 0) and day 90 (inclusive)
|
From randomization (day 0) to day 90 (inclusive)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ventilator-free days through day 28
Tidsramme: From randomization (day 0) to day 28 (inclusive)
|
The number of days from randomization (day 0) to day 28 (inclusive) during which the patient is alive and successfully liberated from invasive mechanical ventilation
|
From randomization (day 0) to day 28 (inclusive)
|
|
Vasopressor-free days through day 28
Tidsramme: From randomization (day 0) to day 28 (inclusive)
|
The number of days from randomization (day 0) to day 28 (inclusive) during which the patient is alive and successfully discontinued from vasopressor therapy
|
From randomization (day 0) to day 28 (inclusive)
|
|
Renal replacement therapy-free days through day 28
Tidsramme: From randomization (day 0) to day 28 (inclusive)
|
The number of days from randomization (day 0) to day 28 (inclusive) during which the patient is alive and does not require renal replacement therapy
|
From randomization (day 0) to day 28 (inclusive)
|
|
28-day all-cause mortality
Tidsramme: From randomization (day 0) to day 28 (inclusive)
|
The proportion of participants who die from any cause between randomization (day 0) and day 28 (inclusive)
|
From randomization (day 0) to day 28 (inclusive)
|
|
In-hospital mortality
Tidsramme: Time Frame: From randomization (day 0) up to hospital discharge, assessed up to 90 days
|
The proportion of participants who die from any cause between randomization (day 0) and hospital discharge (inclusive).
If a patient remains hospitalized for more than 90 days, 90-day mortality will be used as in-hospital mortality
|
Time Frame: From randomization (day 0) up to hospital discharge, assessed up to 90 days
|
|
6-month all-cause mortality
Tidsramme: From randomization (day 0) to 6 months (inclusive)
|
The proportion of participants who die from any cause between randomization (day 0) and 6 months (inclusive)
|
From randomization (day 0) to 6 months (inclusive)
|
|
12-month all-cause mortality
Tidsramme: From randomization(day 0) to 12 months
|
The proportion of participants who die from any cause between randomization (day 0) and 12 months
|
From randomization(day 0) to 12 months
|
|
Decision to withhold or withdraw active treatment during hospitalization
Tidsramme: Time Frame: From randomization (day 0) up to hospital discharge, assessed up to 90 days
|
The proportion of participants in whom active treatment is withheld or withdrawn between randomization (day 0) and hospital discharge (inclusive)
|
Time Frame: From randomization (day 0) up to hospital discharge, assessed up to 90 days
|
|
Telephone Interview for Cognitive Status-Modified (TICS-m)
Tidsramme: 90 days, 6 months and 12 months after randomization
|
Cognitive status was assessed using a Chinese modified version of the Telephone Interview for Cognitive Status-modified (TICS-m).
Higher scores indicate better cognitive performance
|
90 days, 6 months and 12 months after randomization
|
|
Post-Traumatic Stress Disorder (PTSD)
Tidsramme: 90 days, 6 months and 12 months after randomization
|
Psychological outcomes will be assessed with the Post-traumatic Stress Disorder Checklist-Civilian Version (PCL-C, Chinese version).
Respondents indicate how much they have been bothered by a symptom over the past month using a 5-point scale, with higher scores indicating more severe levels of PTSD.
|
90 days, 6 months and 12 months after randomization
|
|
Health-related quality of life (EQ-5D-5L)
Tidsramme: 90 days, 6 months and 12 months after randomization
|
Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) instrument at 90 days, 6months and 12 months after randomization.
The EQ-5D-5L measures health across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
|
90 days, 6 months and 12 months after randomization
|
|
Functional Activities Questionnaire (FAQ)
Tidsramme: 90 days, 6 months, 12 months after randomization
|
Caregiver-reported outcome, higher scores indicating worse impairment.
|
90 days, 6 months, 12 months after randomization
|
|
Activities of daily living (ADL) score
Tidsramme: 90 days, 6 months, 12 months after randomization
|
Assessed using the Barthel Index, including feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair/bed transfer, ambulation, and stair climbing, higher scores indicate greater independence.
|
90 days, 6 months, 12 months after randomization
|
|
Hospital-free days through day 90
Tidsramme: From randomization (day 0) to day 90 (inclusive)
|
The number of days from randomization (day 0) to day 90 (inclusive) during which the patient is alive and does not require hospitalization
|
From randomization (day 0) to day 90 (inclusive)
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of weaning success through day 28
Tidsramme: From randomization (day 0) to day 28 (inclusive)
|
For intubated patients, successful weaning was defined as survival without reintubation within 7 days after extubation, or liberation from invasive mechanical ventilation with ICU discharge within 7 days. For tracheostomized patients, successful weaning was defined as spontaneous breathing via tracheostomy without mechanical ventilation for at least 7 consecutive days, or liberation from invasive mechanical ventilation with ICU discharge within 7 days. Reintubation for diagnostic purposes (e.g., bronchoscopy) or planned surgical procedures (e.g., wound debridement, abdominal lavage, internal fixation of fractures, tracheostomy) was not considered weaning failure. |
From randomization (day 0) to day 28 (inclusive)
|
|
Incidence of gastrointestinal bleeding through day 28
Tidsramme: From randomization (day 0) to day 28 (inclusive)
|
The proportion of participants who developed acute gastrointestinal bleeding requiring transfusion of more than 1 unit of packed red blood cells within 24 hours
|
From randomization (day 0) to day 28 (inclusive)
|
|
Incidence of secondary bloodstream infection through day 28
Tidsramme: From randomization (day 0) to day 28 (inclusive)
|
The proportion of participants who developed secondary bloodstream infection through day 28
|
From randomization (day 0) to day 28 (inclusive)
|
|
Incidence of VAP through day 28
Tidsramme: From randomization (day 0) to day 28 (inclusive)
|
The proportion of participants who developed ventilator-associated pneumonia through day 28
|
From randomization (day 0) to day 28 (inclusive)
|
|
Incidence of hyperglycemia events through day 28
Tidsramme: From randomization (day 0) to day 28 (inclusive)
|
The proportion of participants who had hyperglycemia events (blood glucose level >180 mg/dl) through day 28
|
From randomization (day 0) to day 28 (inclusive)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Jianfeng Xie, MD, Southeast University, Zhongda Hospital
Publikationer og nyttige links
Generelle publikationer
- [1] MATTHAY M A, ARABI Y, ARROLIGA A C, et al. A New Global Definition of Acute Respiratory Distress Syndrome[J]. American Journal of Respiratory and Critical Care Medicine, 2024, 209(1): 37-47. [2] BELLANI G, LAFFEY J G, PHAM T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries[J]. JAMA, 2016, 315(8): 788. [3] LIU L, YANG Y, GAO Z, et al. Practice of diagnosis and management of acute respiratory distress syndrome in mainland China: a cross-sectional study[J]. Journal of Thoracic Disease, 2018, 10(9): 5394-5404. [4] MATTHAY M A, ZEMANS R L, ZIMMERMAN G A, et al. Acute respiratory distress syndrome[J]. Nature Reviews Disease Primers, 2019, 5(1): 18. [5] MEDURI G U, GOLDEN E, FREIRE A X, et al. Methylprednisolone infusion in early severe ARDS[J]. Chest, 2007, 131(4): 954-963. [6] ANNANE D, SÉBILLE V, BELLISSANT E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome*:[J]. Critical Care Medicine, 2006, 34(1): 22-30. [7] TONGYOO S, PERMPIKUL C, MONGKOLPUN W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: Results of a randomized controlled trial[J]. Critical Care, 2016, 20(1): 329. [8] GRASSELLI G, CALFEE C S, CAMPOROTA L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies[J]. Intensive Care Medicine, 2023, 49(7): 727-759. [9] VILLAR J, FERRANDO C, MARTÍNEZ D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial[J]. The Lancet Respiratory Medicine, 2020, 8(3): 267-276. [10] CHRIGUER R S, ROSELINO A M, DE CASTRO M. Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus[J]. Journal of Clinical Immunology, 2012, 32(4): 786-793.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Infektioner
- Luftvejssygdomme
- Systemisk inflammatorisk responssyndrom
- Betændelse
- Lungesygdomme
- Respirationsforstyrrelser
- Patologiske tilstande, tegn og symptomer
- Respiratory Distress Syndrome
- Sepsis
- Polycykliske forbindelser
- Gravidier
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Steroider, fluoreret
- Gravideretrioler
- Dexamethason
- Dexamethason 21-phosphat
Andre undersøgelses-id-numre
- DEFEND Trial
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .